Alec Stranahan

Justin Walsh

Nicole Germino

Li Wang Watsek

Michael Ulz

Brian Kemp Dolliver

David Nierengarten

Etzer Darout

Jeffrey Jones

John Newman

William Maughan

Chiara Montironi

Jeff Jones

Justin Wolf

Mike Ulz

Robert Burns

- Y-mAbs Therapeutics, Inc. (YMAB) completed its **merger** with Yosemite Merger Sub, Inc., a wholly-owned subsidiary of Perseus BidCo US, Inc., on **September 16, 2025**, resulting in YMAB becoming a **wholly-owned subsidiary** of Perseus BidCo US, Inc..  **[1722964_0001104659-25-090232_tm2525998d2_8k.htm:1]** **[1722964_0001104659-25-090232_tm2525998d2_8k.htm:4]** 
- The acquisition was finalized through a **cash tender offer** at **$8.60 per Share**, with approximately **39,827,138 Shares** tendered, representing **87.22%** of outstanding shares.  **[1722964_0001104659-25-090232_tm2525998d2_8k.htm:1]**  The aggregate consideration paid for the Offer and Merger was approximately **$413 million**.  **[1722964_0001104659-25-090232_tm2525998d2_8k.htm:2]** 
- Effective **September 16, 2025**, YMAB's shares were **delisted** from the Nasdaq Global Select Market, and the company intends to deregister its shares and suspend reporting obligations.  **[1722964_0001104659-25-090232_tm2525998d2_8k.htm:3]** 
- Following the merger, the entire Board of Directors and several key officers resigned, and **new directors and officers** were appointed from the acquiring entity.  **[1722964_0001104659-25-090232_tm2525998d2_8k.htm:5]**

Y-mAbs Therapeutics, Inc. Completes Merger and Delists from Nasdaq

Y-mAbs Therapeutics (YMAB)